[1]Poty, Sophie et al. “α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.” Journal of nuclear medicine [2]Yadav, Madhav Prasad et al. “Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metasta...
PSMA[177Lu]Lu-PSMA[225Ac]Ac-PSMAactinium-targeted α-therapyprostate cancer.For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC) who do not respond to [177Lu]Lu-PSMA therapy, there are limited treatment options. Clinical results obtained with [225Ac]Ac-PSMA ...
To date, the patient has received 3 cycles of 225Ac-PSMA with cumulative activity of 22 MBq. He has demonstrated overall great clinical, biochemical (sPSA to 0.2 ug/L) and imaging response to targeted alpha therapy with no significant side effects or toxicity. A restaging 68Ga-PSMA PET/CT...
Alpha-Emitters and Targeted Alpha Therapy in Oncology: From Basic Science to Clinical Investigations. Target. Oncol. 2018, 13, 189–203. [Google Scholar] [CrossRef] Miederer, M.; Scheinberg, D.A.; McDevitt, M.R. Realizing the Potential of the Actinium-225 Radionuclide Generator in Targeted...
In this review, we have summarized and discussed the clinical data of 177Lu-PSMA and 225Ac-PSMA RNT in patients with mCRPC. Keywords: actinium-225; lutetium-177; prostate-specific membrane antigen (PSMA); metastatic castration-resistant prostate cancer (mCRPC); radionuclide therapy (RNT)...
We evaluate imaging and tumor marker response as well as clinical and hematological toxicity of targeted alpha-radiation therapy with Ac-225-PSMA-617 (TAT) in inter-individual comparison to Lu-177-PSMA-617 in dependency of prognostic factors.DOI...
喜欢 0 阅读量: 102 作者: Apostolidis,Christos,Verburg,Frederik,A.,Bruchertseifer,Frank,Kopka,Klaus,Morgenstern 展开 摘要: Prostate-specific membrane antigen (PSMA) is a pro 展开 关键词: PSMA (225)AC alpha-therapy 被引量: 102 年份: 2016 ...
It is the active substance of 177Lu-PSMA-617 and more than 150 clinical-stage therapeutic drug developments across multiple cancer indications. nca Lu-177 is a beta emitter with a half-life of 6.7 days that is free of the long-lived 177mLu. Linked to a cancer-specific targeting agent, ...
Recent clinical studies have shown that the therapeutic application of different prostate-specific membrane antigen (PSMA) inhibitors labeled with 177Lu produce a decrease of more than fifty percent in the prostate antigen (PSA) levels, as well as a significant survival increase (>28 months) in ...
Over recent years, [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced prostate cancer. Especially for alpha particle emitter treatments, there is still a need for improving dosimetry, w